CD274 and neoplasm: Such limitations warrant a search for new immunotherapy biomarkers, such as those based on PD-L1 expression, tumor-infiltrating lymphocytes, TMB, deficient MMR, immune gene signatures, and multiplex immunohistochemistry (Gibney et al., 2016).